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Abstract: 
Background: Many kinase inhibitors have been approved as cancer therapies. Recently, 
libraries of kinase inhibitors have been extensively profiled, thus providing a map of the 
strength of action of each compound on a large number of its targets. These profiled libraries 
define drug-kinase networks that can predict the effectiveness of new untested drugs and 
elucidate the role played by specific kinases in different cellular systems. Predictions of drug 
effectiveness based on a comprehensive network model of cellular signalling are difficult, due 
to our partial knowledge of the complex biological processes downstream of the targeted 
kinases.  
Results: We have developed the Kinase Inhibitors Elastic Net (KIEN) method, which integrates 
information contained in drug-kinase networks with in vitro screening. The method uses the in 
vitro cell response of single drugs and drug pair combinations as a training set to build linear 
and nonlinear regression models. Besides predicting the effectiveness of untested drugs, the 
method identifies sets of kinases that are statistically associated to drug sensitivity in a given 
cell line. We compare different versions of the method, which is based on a regression 
technique known as elastic net. Data from two-drug combinations leads to predictive models, 
and predictivity can be improved by applying logarithmic transformation to the data. The 
method is applied to the A549 lung cancer cell line. A pathway enrichment analysis of the set of 
kinases identified by the method shows that axon guidance, activation of Rac, and semaphorin 
interactions pathways are associated to a selective response to therapeutic intervention in this 
cell line.  
Conclusions: We have proposed an integrated experimental and computational methodology 
that identifies the role of specific kinases in the drug response of a given cell line. The method 
will facilitate the design of new kinase inhibitors and the development of therapeutic 
interventions with combinations of many inhibitors.  
  
Keywords: drug response predictions, kinase inhibitors, regression methods, high throughput 
screening, drug combination therapies. 
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1. Background 
The important role of kinases in cancer biology1 has spurred a considerable effort towards 
the synthesis of libraries of fully profiled kinase inhibitors, providing a map of the strength of 
each compound on a large number of its potential targets.2-4 In particular, a recently published 
dataset has profiled several hundred kinase inhibitors using a panel of more than 300 kinases.4 
These profiled libraries define a network of interactions between drugs and their kinase targets,5 
and represent a valuable resource for the development of new therapies. In this paper, we 
introduce a computational method using information present in profiled libraries and in vitro 
cell response to predict the response of untested drugs. Besides making prediction, the method 
identifies critical kinase targets and pathways that are statistically associated to drug sensitivity 
in a given cell line. 
Statistical inference and regression methods in conjunction with gene expression or 
mutations have been used to identify specific biomarkers associated with an increased 
sensitivity/resistance to drugs. For instance, the sensitivity to PARP inhibitors of Ewing’s 
sarcoma cells with mutations in the EWS gene and to MEK inhibitors in NRAS-mutant cell 
lines with AHR expression have been predicted using analysis of variance and the elastic net 
method6 and then experimentally validated.7,8 In these analyses, the statistical variable 
associated to drugs was represented by the half maximal inhibitory concentration (IC50) in 
different cell lines. However, besides the IC50, many other types of information characterize 
chemical compounds, and these other types of information can be used to enhance the statistical 
analyses and improve the accuracy of predictions. For instance, a method to predict drugs 
sensitivity in cell lines based on the integration of genomic data with molecular physico-
chemical descriptors of the drugs has been recently proposed.9 The residual activity of kinases 
after interaction with a compound is another quantity that can be useful. Kinase profiling, 
patient genetic profiles, and sensitivity of primary leukemia patient samples to kinase inhibitors 
have been recently used by Tyner et al.10 to identify functionally important kinase targets and 
clarify kinase pathway dependence in cancer.  
In this paper, the residual activity of kinases upon drug interaction will be used as 
predictors of the cellular response for in vitro experiments and then integrated in a regression 
method known as elastic net.6 This regression method reduces the number of predictors to a 
minimum set, providing a clear picture of the kinases involved in the sensitive response of cell 
lines.  As training data sets for the regression we will use a primary and a secondary screen 
corresponding to single-drug response and response to combinations of two drugs. The method 
based on two-drug combinations is particularly important due to the current interest in the 
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development of methods for the discovery of therapies based on drug combinations.11 
Moreover, the two-drug screening exhibits a broader distribution in the response and provides 
the models with a good level of predictability. In fact, the model based only on single drug 
response did not pass the statistical cross-validation test.  
We are applying this Kinase Inhibitor Elastic Net (KIEN) method to predict the cell 
viability of a lung cancer cell line (A549) and a normal fibroblast cell line (IMR-90) after drug 
treatment. We found that the regression can be improved through a logarithmic transformation 
on the data. Using the results of the regression, we identified a set of kinases that are strongly 
associated to a response in A549 that is selective with respect to IMR-90. A pathway-based 
enrichment test was done using the results from this kinase analysis. Ten pathways from 
Reactome12 were identified as significant using this set of kinases, including axonal guidance 
and related semaphorin interactions as top hits. 
This paper is organized as follows: We first present in section 2.1 the experimental results 
of the primary and secondary in vitro screening corresponding to single drugs and two-drug 
combinations. These results are analysed in terms of Pearson’s correlation with kinase activity 
in section 2.2. This simple correlation analysis gives a first glance of the kinases that are 
statistically associated to a significant change in the viability of cancer and normal cell lines. In 
section 2.3, we introduce the elastic net approach and we present the results of a leave-one-out 
cross validation for predictions on single and pairs of drugs. We also present in this section the 
results obtained using the logarithmic transformation on the variables and a pathway enrichment 
analysis using Reactome.12 The discussion of the results is in Section 3, conclusions in Section 
4, and Materials and Methods in Section 5. 
 
2. Results  
 
2.1 In vitro screen of the kinase inhibitor library 
Our methodology begins with the experimental screening of single and pairwise drug 
response. The 244 kinase inhibitors (KIs) of our drug library were screened at 1000nM 
individually and the treatment lasted for 72 hours. To quantify a selective response of a cancer 
cell line with respect to a control normal cell line, we define the selectivity 𝑆 of a single drug or 
drug combination as 𝑆 = 𝑣!𝑣!  
where 0≤vN(C)≤1 refers to the viability of normal (N) and cancer (C) cell lines after treatment. 
From the screening of the 244 KIs, the top hit was PDK1/Akt1/Flt3 Dual Pathway Inhibitor 
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(CAS # 331253-86-2) as ranked by selectivity (Figure 1). For the secondary screen we used the 
PDK1/Akt1/Flt3 Dual Pathway Inhibitor as the starting point and combined this compound in 
combination with the other KIs; PDK1/Akt1/Flt3 Dual Pathway Inhibitor was paired with one 
other KIs for a two-drug pair screen. The dose of PDK1/Akt1/Flt3 Dual Pathway Inhibitor was 
optimized to ensure proper dosing range. We found its most selective dose to be 125nM 
(S=10.1± 0.2), while maintaining the normal cell line IMR-90’s viability >90% (Figure 2). We 
used the most selective dose at 125nM and the other 243 KIs at 1000nM for the secondary 
screen. The secondary screen showed that when PDK1/Akt1/Flt3 Dual Pathway Inhibitor was 
paired with another KI, the drug pair presented synergistic effects. The resulting top hit from the 
secondary screen of the library was Alsterpaullone 2-cyanoethyl (CAS # 852529-97-0) with the 
selectivity of kinase inhibitor drug pairs with S= 6.14 (Figure 3). 
 
2.2 Analysis of correlations 
In our second step, we analyzed the Pearson’s correlation of the primary and secondary 
screening with a published dataset4 containing target profiles for 140 kinase inhibitors. 
Therefore, even though we had a library of 244 KIs in the experimental screening, we were 
limited to utilizing 140 KIs for the analysis. For each inhibitor, the dataset provides the residual 
activity (0 ≤ 𝐴 ≤ 1) of 291 kinases after drug treatment. This quantity is a measure of the 
strength of inhibition of a drug on each kinase.  
For each kinase 𝑘, we calculate the Pearson’s correlation, 𝐶!, between the selectivity 𝑆!   and the activities 𝐴!,!, with 𝑖 ∈ 1,… ,𝑀  labeling the single drug or drug pair in the set. For 
drug pairs, the activity is estimated as a product of the residual activities of the two drugs. The 
kinases are then ranked based on the p-value of their correlation with selectivity, and we 
calculate the False Discovery Rate (FDR) adjusted p value.13 The list of kinases mostly 
correlated to the selectivity from the primary and secondary screen are listed in Table 1. A 
similar analysis was done by calculating the correlation between the normal or cancer cell 
viability 𝑣! and the activities. The results for the top kinase-viability correlations for the primary 
and secondary screen are shown in Table 2. Note that, although significant correlations are 
found in both cases, the secondary screen gives stronger correlations than the primary screen. 
 
2.3 Elastic Net regression  
We build a regression model that predicts the response of a cell line to a drug or drug 
combination 𝑖. The response we predict is the normal and cancer cell viability, from which the 
selectivity can be derived. For this purpose, we define a regression problem in which we use the 
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residual activity of the kinase 𝑘 under the effect of drug 𝑖, which we indicate as 𝐴!,!, as 
predictors of the viability. The response can be written as 𝑣! = 𝛽! + 𝛽!𝐴!,! +⋯+ 𝛽!𝐴!,!  .   (1) 
A fitting procedure based on a training set of measurements produces the coefficients (𝛽!,𝛽!,… ,𝛽!). Equation (1) can then be used to predict the viability of a new drug that has not 
been tested, but of which the profiling information is available. Note that we are integrating two 
different types of experimental data: kinase profiling data is obtained through enzymatic assays 
that probe directly the interaction between drug and kinases, while the in vitro cell response data 
is the result of complex signaling that involves many pathways downstream of the affected 
kinases. The coefficients 𝛽! can be seen as a measure of the sensitivity of a given cell line due 
to alterations in the activity of kinase 𝑘. 
It is well known that the least square method does not perform well in the case of linear 
regression with many predictors. In our case, we would like to use a database of drugs that have 
been profiled on about 300 kinases. However, it would be desirable to select and keep in the 
final model a minimal set of the kinases that perform well as predictors and provide a simple 
model, useful to gain biological insight. The lasso technique14 is a powerful method to reduce 
the number of predictors by imposing a penalty on the regression coefficients.  However, in the 
presence of a group of kinase predictors with strong mutual correlation, the lasso could select 
only one kinase predictor from the group while missing the others. To prevent this problem, our 
method uses the elastic net approach. This method incorporates the lasso penalty as well as a 
ridge penalty to keep the regression coefficients small without completely removing them.6 The 
weights of the ridge and lasso penalties in the least square procedure can be optimized for best 
performance of the method.    
We show in Figure 4 (a) and (b) the results of a leave one out cross validation 
(LOOCV) method for the primary (a) and secondary screen (b). For each of the 140 drugs, we 
apply the elastic net method using the remaining 139 drugs and then we compare the result to 
the measured value. This cross validation method is a particular case of the more general k-fold 
cross validation procedure in which k is equal to the size of the training set.15 The cross LOOCV 
shows that the information contained in the primary screen is not sufficient to define a 
predictive model. The fact that some kinases in Tables 1 and 2 show some significant 
correlation with the response when considered individually is in general not a sufficient 
condition for defining a predictive multiple regression model.  On the other hand, the secondary 
screen is able to reproduce the viability of many drugs, especially the ones with the stronger 
effect on both cell lines. Overall, the data from the secondary screen presents a much broader 
distribution with a tail representing a few drug combinations particularly effective. The 
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regression works better in identifying these highly effective pairwise combinations and the 
relative ranking of their strengths. Data is not particularly informative for drugs and drug 
combinations that are not effective, which concentrate in the neighborhood of ~1 . 
Data transformations can represent a powerful strategy to improve regression. We 
applied a logarithmic transformation, which is consistent with the hypothesis of an independent 
action on the different kinases on the total viability. We write the viability as 𝑣! = 𝑒!! 𝐴!,! !! ⋅ 𝐴!,! !! ⋅ … ⋅ 𝐴!,! !!   .  (2) 
By applying a log transformation on both sides of Eq. (2) we reduce the problem to a linear 
regression, to which the elastic net strategy can be applied. We show in Figure 5 the results of 
the LOOCV for the primary and secondary screen using the logarithmic data transformation.  
As in the linear case, we find that the method fails the cross validation procedure if we use data 
from the primary screen, while the secondary screen with log transformed data gives better R2.  
In addition to a regression model that can be used to predict the efficacy of drugs that 
have not been tested, the 𝛽! coefficients can be used to rank kinases in terms of their relevance 
in the regression. These coefficients therefore identify the kinases whose inhibition is associated 
to a decrease in the cell viability. A ranking based on the differential 𝛽!! − 𝛽!!, where the index 
N and C identify the regression model of the cancer and normal cells, gives insight on specific 
pathways important for a selective response of cancer cells. Table 3 show a list of kinases 
ranked in terms of 𝛽!! − 𝛽!! , where the coefficients have been obtained using the logarithmic 
data transformation on the secondary screen, which, as seen above, is the best performing 
method according to our cross validation.  
In order to test whether selected pathways were significantly enriched for the identified 
kinase genes in Table 3, a pathway-based enrichment analysis was conducted using the results 
from the kinase analysis and Fisher exact tests. Ten pathways from Reactome were identified as 
significant (p<0.05) using this kinase list, including axon guidance, activation of Rac, and 
semaphorin interactions as top hits (Table 4).  
 
3. Discussion 
Drug-kinase profiling represents a controller-target network5 that when combined with in 
vitro testing, can be used in regression models to predict response and identify pathways 
statistically associated to drug sensitivity. Network methods in biology are often based on the 
analysis of large datasets from high-throughput experiments. An example is given by gene 
regulatory networks, which presents many challenges either when restricted to a homogeneous 
set of data16,17 or when it includes different classes of data.18-21 In our KIEN method, 
7 
information from the drug-target network and experimental query of the biological system are 
integrated. The goal is not a reconstruction of a regulatory network, but we wish to identify a set 
of kinases linked to a therapeutic response in a given cell line. In order to establish associations, 
the system has to be perturbed by the use of kinase inhibitor drugs. The response to these drugs 
or drug combinations provides a training set that when combined with the profiling, can lead to 
predictions.  
The Elastic Net method is one of the most widely used regularization techniques. 
Regularization techniques are used in statistical and machine learning models to achieve an 
optimal tradeoff between accuracy and simplicity. Simplicity makes a model less prone to 
overfitting and more likely to generalize. In our analysis, we found that the elastic net 
regressions based on single drug responses were not successful, while drug pair data provided 
statistically significant predictions. A possible explanation for this finding is the following:  
single drugs might be less able to overcome the robustness of biological networks. The 
phenotypic signal is therefore blunted and not easily measured. If a second drug is added, any 
compensatory capacity is already stretched and the effects from the inhibition of each kinase 
can be seen more clearly. Using data from drug pairs, we found that noise can be better filtered 
out and stronger statistical associations between kinases and therapeutic response are revealed.  
Clearly, if a different training set of more effective drugs were used in the primary screen, it is 
likely that also single drug in vitro response would have given a significant predictive model.  
Among the top three pathways shown in Table 4 are activation of Rac and  Semaphorin 
interactions. Rac proteins play a key role in cancer signaling and belong to the RAS 
superfamily.22 We also identified a set of semaphorins in our analysis that is represented in the 
top significantly enriched pathways. Semaphorins, previously known as collapsins, are a set of 
proteins containing a 500-amino acid sema domain among others (including PSI and 
immunoglobulin type domains), which can be transmembranous or secreted.23 It is known that 
Sema3E cleavage promotes invasive growth and metastasis in vivo.23 These genes also have 
selected targeting by Rac and Rho family members. This generates hypotheses of possible 
pathways that could be targeted therapeutically. 
 
4. Conclusions 
We have introduced an integrated experimental and computational methodology that 
identifies the role of specific kinases in the drug response of a given cell line. The key element 
of our KIEN methodology is a multiple regression procedure that uses in vitro screen data as a 
training set. Were a new library of kinase inhibitor compounds be synthetized and profiled, our 
model would then be able to immediately estimate the effect of these drugs on in vivo 
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experiments on a given cell line. We have shown an applications to a lung cancer cell line, but 
the method be extended to different cell lines. The method will facilitate the design of new 
kinase inhibitors and the development of therapeutic interventions with combinations of many 
inhibitors. The procedure could be extended to three drug combinations, if measurements for 
these larger combinations were available. Finally, the method could be extended to regression 
models that are specific of cancer cells with the same set of mutations, or it could be directly 
used with patient-derived primary cells to identify a personalized treatment. 
 
5. Materials and Methods 
Materials 
The primary screening of a kinase inhibitor (KI) library comprised of 244 KIs was 
purchased from EMD Chemicals, and diluted with DMSO to 2mM concentrations for high-
throughput screening purposes. The KI library was stored at -80°C. Additionally, 
PDK1/Akt1/Flt3 Dual Pathway Inhibitor (CAS # 331253-86-2) was ordered from Calbiochem. 
Only 140 out of 244 were used in the drug-target network reconstruction because drug profiling 
information was available only for these compounds. One kinase inhibitor known to affect the 
kinase targets indirectly was excluded. 
 
Cell Culture 
Cell lines IMR-90 (normal lung fibroblast) and A549 (lung adenocarcinoma) were 
cultured in RPMI 1640 (Hyclone) supplemented with 10% Canadian characterized fetal bovine 
serum (Hyclone), 1% 200mM L-glutamine (Omega), and 1% penicillin/streptomycin (Omega). 
The media for the cells were renewed every 3 days and kept at 80-90% confluency. Cells were 
maintained in a humidified environment at 37°C and 5% CO2.  
 
Kinase Inhibitor Experiments 
IMR-90 (1500 cells/well) and A549 (750 cells/well) were seeded on 384-well 
microplates (Grenier Bio-One) and incubated for 3 hours before the addition of kinase 
inhibitor(s). IMR-90 and A549 cell lines were tested on the same day with three replicates and 
the experiment was repeated three times with randomized well positions to reduce biases. 
ECHO 555 Liquid Handler (Labcyte) was used to dispense nanoliter volumes of each KI to 384-
well plates with cells attached (wet dispense). The final volume in the plate is 40uL and cells 
were incubated for 72 hours with KI treatment.  
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ATP Measurements 
ATPlite 1Step (Perkin Elmer) was used to evaluate the cell number and cytotoxicity. 
ATP measurements were done by dispensing 20uL of the ATPlite 1Step solution to each well 
with the final volume of 60uL. The plate was placed on a shaker at 1100rpm and luminescence 
activity was detected by Analyst GT Plate Reader. The percent (%) of control is the quantity of 
ATPlite 1step measurement of the treated versus the untreated wells of each individual cell type. 
The selectivity, S, is defined as selectivity= (IMR-90/cell type) as indicator of the kinase 
inhibitor’s selective control of the kinase in the cancerous cell line (A549) over the normal cell 
line (IMR-90).  
 
Computational Methods 
Correlations between selectivity/viability and kinase activity were calculated using the 
python scipy linregress function, which also provide p-values. FDR were then obtained by 
ranking the p-values and directly applying the Benjamini–Hochberg procedure. The elastic net 
regression was carried out using the Scikit-learn package24 which finds the coefficients 𝛽 that 
minimize the function 𝐹 = !!  ! | 𝑣 − 𝐴𝛽 |!! + 𝛼𝜌| 𝛽 |! + !!𝛼 1 − 𝜌 ||𝛽||!! , 
where 𝑣 is the vector of the observed viabilities and 𝐴 is  the matrix containing the residual 
activity of the kinases from the profiling. The parameters 𝛼 and 𝛽 determine the relative weights 
of the lasso and ridge penalties quantified using 𝐿!  (|| ∙ ||!  ) and 𝐿!  (|| ∙ ||!) norm, respectively. 
We used 𝛼 = 0.15 and 𝜌 = 0.01 in the results of Figures 4 and 5 and in Table 3. We also tried 
other values of these parameters, which did not give a significant difference in the results. 
 
Pathway-based enrichment 
Reactome pathways were downloaded using a newer build of the ‘biomaRt’ library  
(v2.12.0) in Bioconductor /R (v2.15.0). Gene symbols from the kinase list were converted to 
Entrez gene identifier numbers (‘entrezgene’) and mapped against the gene ids in each 
Reactome pathway. For each pathway, the set of significant genes enriched within any given 
pathway was computed using a Fisher exact test.  The procedure computes the significance (p-
value) of observing significant kinases, as deemed significant by our method, within the 
selected pathway. Given that our gene set consists entirely of kinases and would be generalized 
towards kinase-specific effects, the set of all kinases (~300) were selected for background 
adjustment and more sensitive enrichment of the pathways.  This procedure was repeated for 
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each pathway to generate p-values and pathway rankings.  False discovery rate [FDR] values 
were later generated to further restrict significance. 
 
The data sets supporting the results of this article are included within the article. Authors’ 
contributions: GP & CP proposed concept, EO, CP and APH performed calculations, TT 
performed experiment, CP and GP wrote the manuscript. Correspondence and requests for 
materials should be addressed to giovanni@sanfordburnham.org or carlo@pa.msu.edu. 
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FIGURES 
 
 
 
Figure 1. Primary screen results of the top ten most selective kinase inhibitors. The 3 digit code 
is the in-house code. A15: PDK1/Akt1/Flt3 Dual Pathway Inhibitor. 
 
 
 
Figure 2. Optimization of PDK1/Akt1/Flt3 Dual Pathway Inhibitor. Lower doses of 
PDK1/Akt1/Flt3 Dual Pathway Inhibitor were tested to see the response of A549 to the drug. 
The doses are 31.25nM, 62.5nM, 125nM, 250nM, 500nM, and 1000nM.  
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Figure 3. Secondary screen results of the top ten most selective drugs (1000nM) when paired 
with PDK1/Akt1/Flt3 Dual Pathway Inhibitor (125nM). The 3 digit code is the in-house code. 
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 Leave-one-out Cross Validation 
 
   
 
Figure 4: Leave-one-out Cross Validation of the elastic net regression model based on the 
primary (top) and secondary (bottom) screens for normal and cancer cell lines. Each of the 140 
point in these figures corresponds to one of the 140 drug. “Regression” refers to the viability 
predicted by the regression model using all data from the other 139 drugs as training set, while 
“Expected” refers to the actual viability measured for the drug or drug combination. Note that 
only the secondary screen leads to predictive models with significant R2 for the two cancer cell 
types. 
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Leave one out cross validation: Log transformed data 
 
 
   
 
  
 
Figure 5: Leave-one-out Cross Validation of the elastic net regression model based on the 
primary (top) and secondary (bottom) screens for normal and cancer cell lines after logarithmic 
transformation on the data. Each of the 140 point in these figures corresponds to one of the 140 
drug. “Regression” refers to –log of the viability predicted by the regression model using all 
data from the other 139 drugs as training set, while “Expected” refers to –log of the actual 
viability measured for the drug or drug combination. Note that, as in Figure 4, only the 
secondary screen leads to predictive models with significant R2 for both cell types. The R2 for 
the Cancer cell lines is considerably better using the log transformation. 
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TABLES 
 
Kinase Selectivity	  Corr FDR 	   Kinase Selectivity	  Corr FDR 
Primary	  screening 	   Secondary	  Screening 
PRKCZ 0.451 2.28E-­‐08 TGFBR2 -­‐0.501 8.29E-­‐08 
DMPK 0.435 7.75E-­‐08 CDK4 -­‐0.412 6.40E-­‐05 
STK39 0.430 1.15E-­‐07 CDC42BPB -­‐0.409 6.40E-­‐05 
EPHA8 0.420 2.33E-­‐07 RIPK2 -­‐0.399 7.73E-­‐05 
ADRBK2 0.399 1.01E-­‐06 DSTYK -­‐0.369 0.000413 
PRKACG 0.396 1.27E-­‐06 ACVRL1 -­‐0.368 0.000413 
CAMK4 0.394 1.45E-­‐06 PAK1 -­‐0.367 0.000413 
MAP2K2 0.393 1.53E-­‐06 MAPKAPK2 -­‐0.364 0.000413 
ADRBK1 0.392 1.62E-­‐06 PAK7 -­‐0.359 0.000424 
PNCK 0.382 3.29E-­‐06 CDK1 -­‐0.357 0.000429 
 
Table 1 Correlations between selectivity and kinase activity from primary and secondary 
screening. 
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Kinase Normal	  Viab	  Corr FDR 	   Kinase Normal	  Viab	  Corr FDR 
Primary	  screening 	   Secondary	  Screening 
ADRBK1 0.484 3.92E-­‐07 PAK1 0.653 6.23E-­‐16 
DMPK 0.481 3.92E-­‐07 PAK3 0.647 8.53E-­‐16 
DDR2 0.459 1.15E-­‐06 PKN2 0.619 3.32E-­‐14 
ZAP70 0.455 1.16E-­‐06 PDPK1 0.605 1.86E-­‐13 
AKT2 0.453 1.16E-­‐06 SIK2 0.575 6.37E-­‐12 
CAMK1G 0.427 6.99E-­‐06 MAP3K10 0.568 1.22E-­‐11 
TSSK2 0.428 6.99E-­‐06 FGFR2 0.562 1.98E-­‐11 
MAPKAPK2 0.424 6.99E-­‐06 CAMK2G 0.561 2.14E-­‐11 
CAMK4 0.423 6.99E-­‐06 CDC42BPB 0.559 2.20E-­‐11 
PRKCZ 0.419 7.54E-­‐06 NUAK2 0.545 9.97E-­‐11 
 
Kinase Cancer	  Viab	  Corr FDR 	   Kinase Cancer	  Viab	  Corr FDR 
Primary	  screening 	   Secondary	  Screening 
AKT2 0.549 6.01E-­‐10 PAK1 0.625 4.51E-­‐14 
DMPK 0.545 6.01E-­‐10 PKN2 0.567 4.33E-­‐11 
CAMK1G 0.528 1.87E-­‐09 PAK3 0.554 1.25E-­‐10 
DDR2 0.506 1.35E-­‐08 MAP3K10 0.550 1.43E-­‐10 
ZAP70 0.493 3.67E-­‐08 CDC42BPB 0.539 3.81E-­‐10 
CAMK4 0.488 4.50E-­‐08 MAP3K2 0.520 2.16E-­‐09 
ADRBK1 0.477 1.07E-­‐07 PDPK1 0.519 2.16E-­‐09 
SGK3 0.477 1.07E-­‐07 SIK2 0.519 2.16E-­‐09 
GRK5 0.473 1.20E-­‐07 NUAK2 0.502 8.14E-­‐09 
AKT1 0.454 5.09E-­‐07 FES 0.502 8.14E-­‐09 
 
Table 2 Correlation between viability of normal (top) and cancer (bottom) cell lines and kinase 
activity from primary and secondary screening. 
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Kinase	   Cancer	  beta	  	  
coefficient	  
Normal	  beta	  
coefficient	  
Difference	  
TGFBR2	   0.061	   0.000	   0.061	  
EGFR	   0.060	   0.000	   0.060	  
PHKG1	   0.051	   0.014	   0.037	  
RIPK2	   0.032	   -­‐0.002	   0.034	  
PRKG2	   0.012	   0.045	   0.033	  
CDK4	   0.021	   -­‐0.008	   0.029	  
MAP3K10	   0.038	   0.014	   0.024	  
MARK4	   0.000	   0.022	   0.022	  
PAK1	   0.025	   0.004	   0.021	  
MAP4K5	   0.021	   0.000	   0.021	  
MARK2	   0.006	   0.026	   0.021	  
MARK3	   0.000	   0.020	   0.020	  
TBK1	   0.012	   0.031	   0.020	  
ERBB2	   0.021	   0.001	   0.019	  
NUAK1	   -­‐0.029	   -­‐0.010	   0.019	  
ULK2	   0.018	   0.000	   0.018	  
MYLK2	   -­‐0.024	   -­‐0.006	   0.018	  
MAP4K4	   0.004	   -­‐0.014	   0.018	  
CDK5	   0.002	   -­‐0.016	   0.018	  
GSK3B	   0.021	   0.004	   0.017	  
PAK2	   0.019	   0.002	   0.017	  
CDC42BPB	   0.023	   0.006	   0.017	  
DSTYK	   0.006	   -­‐0.010	   0.016	  
RPS6KA2	   0.000	   -­‐0.016	   0.016	  
FGFR1	   -­‐0.004	   0.012	   0.016	  
PAK7	   0.015	   0.000	   0.015	  
PIM1	   -­‐0.015	   0.000	   0.015	  
CDK3	   0.015	   0.000	   0.015	  
IRAK1	   -­‐0.002	   -­‐0.017	   0.015	  
 
Table 3. Kinases with the highest difference in the regression coefficients for the log 
transformed data of the secondary screen.  
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Path	  ID	   Path	  name	   NS	   NT	   p-­‐val	  
422475	   Axon	  guidance	   8	   31	   0.006	  
428540	   Activation	  of	  Rac	   3	   5	   0.008	  
373755	   Semaphorin	  interactions	   4	   10	   0.011	  
376176	   Signaling	  by	  Robo	  receptor	   3	   7	   0.024	  
1266738	   Developmental	  Biology	   8	   39	   0.026	  
445144	   Signal	  transduction	  by	  L1	   4	   13	   0.030	  
373760	   L1CAM	  interactions	   4	   14	   0.040	  
193639	   p75NTR	  signals	  via	  NF-­‐kB	   2	   4	   0.051	  
209543	   p75NTR	  recruits	  signalling	  complexes	   2	   4	   0.051	  
389359	   CD28	  dependent	  Vav1	  pathway	   2	   4	   0.051	  
 
Table 4.  Reactome pathways with significant representation of kinases from the regression 
analysis.  Ns indicates the number of kinases that are found significant in the regression analysis, 
while NT is the total number of kinases in the pathway. The top nine pathways with Fisher exact 
test p<0.051 are shown. These pathways are identified from 518 Reactome pathways containing 
at least one of the kinases identified in Table 3. 
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